# Journal of Medicinal Chemistry

Article

Subscriber access provided by MICHIGAN STATE UNIVERSITY | MSU LIBRARIES

# Structure diversification of vancomycin through peptidecatalyzed, site-selective lipidation: A catalysis-based approach to combat glycopeptide-resistant pathogens

Sabesan Yoganathan, and Scott J. Miller

J. Med. Chem., Just Accepted Manuscript • DOI: 10.1021/jm501872s • Publication Date (Web): 11 Feb 2015 Downloaded from http://pubs.acs.org on February 18, 2015

# **Just Accepted**

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



Journal of Medicinal Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Structure diversification of vancomycin through peptide-catalyzed, site-selective lipidation: A catalysis-based approach to combat glycopeptide-resistant pathogens

Sabesan Yoganathan<sup>*a,b*</sup> and Scott J. Miller<sup>\**a*</sup>

<sup>a</sup>Department of Chemistry, Yale University, P.O. Box 208107, New Haven, CT 06520-

<sup>b</sup> Current address: Department of Pharmaceutical Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439

\*To whom correspondence should be addressed. e-mail: scott.miller@yale.edu

KEY WORDS: vancomycin, glycopeptides, infectious diseases, antibiotics, peptide catalysis, site-selective chemistry, vancomycin-resistant bacteria

# ABSTRACT

 Emergence of antibiotic-resistant infections highlights the need for novel antibiotic leads, perhaps with a broader spectrum of activity. Herein, we disclose a semisynthetic, catalytic approach for structure diversification of vancomycin. We have identified three unique peptide catalysts that exhibit site-selectivity for the lipidation of the aliphatic hydroxyls on vancomycin, generating three new derivatives **9a**, **9b** and **9c**. Incorporation of lipid chains into vancomycin scaffold provides promising improvement of its bioactivity against vancomycin-resistant enterococci (Van A and Van B phenotypes of VRE). The MICs for **9a**, **9b**, and **9c** against MRSA and VRE (Van B phenotype) range from 0.12 to 0.25  $\mu$ g/mL. We have also performed a structure activity relationship (SAR) study to investigate the effect of lipid chain length at the newly accessible G<sub>4</sub>-OH derivatization site.

#### **INTRODUCTION**

Natural products and their structural derivatives continue to be the lead therapeutics for the treatment of various diseases.<sup>1-3</sup> In particular, numerous antibiotics approved for clinical applications have been either natural products or their derivatives.<sup>4</sup> Emerging problem of drug resistance highlights the need for new drug leads to combat infectious diseases, perhaps via development of novel synthetic analogues of existing bioactive molecules.<sup>4-6</sup> Synthetic endeavors to modify natural products can be a challenging task due to their structural complexity and the presence of a large array of reactive functional groups.<sup>2.7</sup> As such, efficient and highly selective approaches that employ minimal protecting group manipulations are desirable. In recent years, catalyst

#### **Journal of Medicinal Chemistry**

dependent diversification of complex drug molecules has gained considerable interest.<sup>8-11</sup> Many important approaches, including biocatalysis, may be brought to bear on the problem.<sup>12</sup>

Our research group (Figure 1)<sup>13-18</sup> and others<sup>19,20</sup> have demonstrated that synthetic oligopeptide-based catalysis enables a wide range of chemical transformations to derivatize polyol natural products of medicinal interest.<sup>10,21,22</sup> For example (Figure 1a), we have developed peptide-based catalyst wherein the critical catalytic residue p(methyl)-histidine (Pmh) is central to the selective transfer of acyl groups,<sup>13</sup> phosphoryl groups,<sup>23</sup> sulfur-based electrophiles<sup>24,25</sup> to individual sites in structures containing multiple hydroxyl groups. As an example in the context of complex glycopeptides like vancomycin (**1a**), we also showed that catalytic thiocarbonylation – as a prelude to site-selective deoxygenation – could be enabled with the Pmh-based catalyst construct, allowing excision of either the G<sub>6</sub>-oxygen atom, or the Z<sub>6</sub>-oxygen atom, in a catalyst-dependent manner (Figure 1b).<sup>15</sup>

### **Please Insert Figure 1**

**Figure 1.** (a) A schematic outline of various group transfer reactions catalyzed by Pmhbased peptides for polyol modifications. (b) A representative set of catalyst-dependent maneuvers leading to two unique deoxygenation vancomycin analogues.<sup>15</sup>

Catalytic, site-selective acyl transfer reactions of long-chain fatty acid functionality (i.e., lipidation) present a particularly intriguing avenue for the synthesis of positional isomers of lipidated analogues of glycopeptide-based polyols. Lipid groups in

lipopeptide and lipoglycopeptide antibacterial natural products have been implicated in their potency<sup>26-29</sup> and such modifications enable medicinal chemists to tune the bioactivity of antibacterial natural products.<sup>28,30,31</sup> We describe in this paper several advances in the use of Pmh-based catalysts for the preparation of site-selectively lipidated vancomycins, along with data on their biological activity.

The glycopeptide vancomycin and the teicoplanins, lipoglyco-peptides (Figure 2, **1a** and **2**) are potent antibiotics for the treatment of several drug resistant bacterial infections, including methicillin-resistant *Staphylococcus aureus* (MRSA).<sup>26,32,33</sup> Glycopeptides and lipoglycopeptides bind to the 'Lys-<sup>D</sup>Ala-<sup>D</sup>Ala' peptide region of peptidoglycan monomer, which leads to inhibition of bacterial cell wall biosynthesis, and cell death. Due to its unique mode of action and potency, vancomycin has been an antibiotic of interest for synthetic modifications in order to target drug-resistant pathogens.<sup>7,32,34-40</sup> In particular, several analogues containing lipid motifs at the chemically most accessible positions on vancomycin (V<sub>3</sub>-NH<sub>2</sub>, X<sub>1</sub>-NHMe, or G<sub>6</sub>-OH, Figure 2) have been reported, which exhibit improved antibacterial activity against glycopeptide-resistant bacteria.<sup>34,35,37</sup>

#### **Please Insert Figure 2**

Figure 2. Structures of vancomycin (1a), a G<sub>6</sub>-modified vancomycin (1b), and

teicoplanin  $A_2$ -2 (2)

Differentiating the reactivity of six aliphatic hydroxyls, the phenolic OH-group and the resorcinol-like OH-groups on vancomycin is a challenging task. This has restricted comprehensive structural modifications on the peripheral hydroxyls of vancomycin to date. Moreover, limited knowledge is available regarding the importance of these functional groups on structure and bioactivity. Our recent study of the catalytic synthesis of two deoxy-vancomycin analogues noted above revealed biological consequences.<sup>15</sup> Z<sub>6</sub>-Deoxy-vancomycin exhibits conformational heterogeneity, and modified potency in MIC assays. We speculate that additional perturbations to the hydroxyl group array of vancomycin would also unveil additional modulation of biological activity. Related observations followed our discovery of catalysts for the siteselective phosphorylation of hydroxyls within the teicoplanin A<sub>2</sub>-2 structure.<sup>18</sup>

Moreover, based on the heightened bioactivity of alkyl- and acyl-vancomycin analogues and teicoplanins, <sup>41,42</sup> we hypothesized that site-selective lipidation of vancomycin would yield structurally diverse and biologically promising analogues. In this vein, previous studies suggest that hydrophobic groups on vancomycin greatly improve its potency via at least two distinct proposed mechanisms: (i) enhancement of proximity induced binding of vancomycin analogues to peptidoglycan monomer via bacterial cell membrane association<sup>31,43,44</sup>; (ii) binding of lipidated vancomycin derivatives to transglycosylase and inhibition of cross-linking of disaccharides during peptidoglycan biosynthesis.<sup>45,47</sup> The research described below culminates in the discovery of three unique peptide-based catalysts for site-selective incorporation of lipid motifs at the  $G_6$ ,  $G_4$ , and  $Z_6$  positions on vancomycin. Each is portable for the transfer of acyl side chains of varying length, leading to a library of previously unknown vancomycin

analogues. Their structural characterization and the antibacterial activity are also disclosed.

#### **RESULTS AND DISCUSSION**

#### Chemical catalysis

Based on previous studies, we began with the synthesis of a partially allylprotected vancomycin (**3**) in order to gain desirable solubility in organic solvents, and prevent undesired reactions with amines, phenols or resorcinol-like OH-groups of **1a**.<sup>48</sup> Since vancomycin is readily available from commercial sources, we synthesized **3** on multi-gram scale (15 g) via a sequential formation of alloc-carbamates, ally-ester and allyl-ethers.<sup>15,48,49</sup> From our initial screening, we found that symmetric anhydrides worked well for the acyl-transfer reactions; while acyl chlorides showed unselective reactivity and *N*-hydroxysuccinimide active esters were not reactive under the reaction conditions.

Under optimized reaction conditions, **3** exhibited no reactivity towards an anhydride in the absence of a nucleophilic catalyst, and negligible reactivity in the presence of *N*-methylimidazole (NMI) as an achiral control catalyst. Once we established a sense of the background reactivity, we investigated a library of peptide-based catalysts for the acyl-transfer reaction. All of these peptides contain the catalytic amino acid Pmh, which assists in the acyl transfer reaction. For this study, we investigated two parallel approaches to identify catalysts to achieve site-selective lipidation: (i) screening of catalysts from legacy peptide-based catalysts in our laboratory. (These catalysts and their analogues have been previously explored for regioselective or enatioselective reactions.<sup>50,51</sup>), and (ii) Screening of catalyst structures designed by placing the Pmh

Page 7 of 44

residue within the 'Lys-<sup>D</sup>Ala-<sup>D</sup>Ala' scaffold. Analysis of a X-ray crystal structure of vancomycin-ligand complex (Figure 3)<sup>52</sup> and our previous findings<sup>15</sup> suggest that placement of the Pmh residue proximal to disaccharides on vancomycin often yields selective modification of the hydroxyls based on this binding model.<sup>15-18</sup>

# **Please Insert Figure 3**

**Figure 3.** (a) a co-crystal structure of the ligand, N-Ac-Lys(Ac)-<sup>D</sup>Ala-<sup>D</sup>Ala (yellow) bound to vancomycin and (b) a drawing of a segment of a designed catalyst over the ligand (PDB 1FVM).<sup>52</sup>

Since numerous lipopeptides and lipoglycopeptides (i.e. daptomycin. teicoplanins) generally contain a decanoyl-group as the lipid motif, we began the lipidation chemistry using decanoic anhydride as the longest lipid chain. We first screened a collection of 25 catalysts from the legacy peptide library. Starting material **3** was reacted with decanoic anhydride (2 equiv), 1,2,2,6,6-pentamethylpiperidine (PEMP, 2 equiv), and catalyst (20 mol%) in 3:1 CH<sub>2</sub>Cl<sub>2</sub>/THF (0.007 M) for 24 h (Figure 4 and Scheme 1). Intriguingly, the peptide catalysts exhibited superior reactivity compared to NMI, and provided reasonable conversion to the decanoyl-vancomycin derivatives (See Supporting Information for details). In fact, we identified several catalysts that yielded a mixture of  $G_6$  and  $G_4$ -products in very high conversion, including catalyst 5. Each product was characterized using a combination of LC-MS/MS fragmentation analysis, and 2D-NMR spectroscopy to elucidate the site of modification (see Supporting Information).

### **Please Insert Scheme 1**

Scheme 1. Exploration of catalysts for site-selective modification of 3.

#### **Please Insert Figure 4**

Figure 4. RP-HPLC traces for uncatalyzed, NMI (0.2 equiv) catalyzed, and peptide 5 catalyzed reactions of 3 using decanoyl anhydride.

Within the first set of legacy library, we were pleased to identify catalysts 6 and 7 for selective modification of the  $G_4$  (4a:4b:4c = 1:5:0, 87% conv. of 3) and  $Z_6$  (4a:4b:4c = 0:1:17, 94% conv. of 3) hydroxyls respectively.<sup>53</sup> It is worth noting that 6 and 7 were historically relevant to us, having been previously identified as hit catalysts for the kinetic resolution of formamides,<sup>54</sup> and for the asymmetric phosphorylation of *myo*-inositol,<sup>23</sup> respectively. Moreover, 7 was also a key catalyst for the  $Z_6$ -selective thiocarbonylation of vancomvcin.<sup>15</sup> Interestingly, no catalyst from the legacy peptide library delivered G<sub>6</sub>selectivity. Thus, we turned our attention to the second approach, where rationally designed 'Xaa-<sup>D</sup>Ala-<sup>D</sup>Pmh' type catalysts were evaluated. As this approach had been successful previously, allowing observation of high selectivity for G<sub>6</sub>-position for thiocarbonylation, we hoped its selectivity would carry over to the transfer of a different reagent. Strikingly, catalyst 8, which was a hit catalyst for the  $G_6$ -selective thiocarbonylation<sup>15</sup> also yielded good selectivity for the acylation of the  $G_6$ -position (4a:4b:4c = 6:1:0, >99% conv. of 3).<sup>53</sup> It is gratifying that we rediscovered new reactivity and selectivity for 6, 7 and 8, which suggests that these 'legacy catalysts' are very

#### Journal of Medicinal Chemistry

versatile for various group transfer reactions. This state of affairs is observed in some cases as different types of electrophiles, but not all, as we have observed previously.<sup>15</sup> Nevertheless, a set of catalysts selective for three distinct hydroxyl groups within vancyomycin ( $G_{6^-}$ ,  $Z_{6^-}$  and  $G_{4^-}$ , with  $G_{4^-}$  being previously unknown in our experience) represents an expansion of catalytic capabilities for derivatization of this particular structure.

#### **Please Insert Figure 5**

Figure 5. Structures of catalysts identified for selective lipidation.

#### **Please Insert Figure 6**

Figure 6. RP-HPLC traces for catalyst dependent reactivity of 3 with decanoyl anhydride. (a)  $G_4$ -selective catalysis with 6, (b)  $Z_6$ -selective catalysis with 7, and (c)  $G_6$ -selective catalysis with 8.

Although the catalyst dependent acyl-transfer reaction enables modification of the various hydroxyls, we wanted to confirm that the selectivity observed is not due to an internal, intramolecular acyl group migration among the hydroxyls within a glucose ring. More specifically, we wanted to ensure that conversion of **4a** into **4b** is not occurring under the reaction condition. To investigate this, we prepared pure samples of **4a** and **4b** 

and subjected them to the reaction condition (Scheme 2). Since 2 equiv of PEMP was used for the optimized acylation reaction to modify vancomycin, we subjected the products (4a and 4b) to the same reaction condition to evaluate the acyl migration pathway. We were pleased to find that **4a** remained stable in the presence of up to 2 equiv of PEMP for 20 h, suggesting that the  $G_6$ -acyl group (4a) is not migrating to  $G_4$ -position (4b). When 4b was treated with 2 equiv of PEMP, it was stable for up to 5 h; however, at 20 h, 4b progressively equilibrated to 4a (4a: 4b = 1:1, see supporting materials), indicating under strong basic conditions, the acyl group at  $G_4$ -position migrated to the  $G_6$ position. Yet, when only 0.5 equiv of PEMP was used, there was no equilibration of 4b to 4a for up to 20 h. These findings suggest that the migration is not occurring under mild basic condition (with 0.5 equiv PEMP). In addition, when acylation reactions (Scheme 1) were monitored over 24 h, 30 h and 40 h intervals, no change in selectivity was observed, perhaps indicative of a buffering effect wherein the RCO<sub>2</sub>H byproduct of the anhydride inhibits migration. Taken together, we believe that both 4a and 4b are formed in a catalyst-dependent manner under kinetic control under our catalytic reaction conditions, and once these products are formed, they remain stable under the reaction condition.

#### **Please Insert Scheme 2**

Scheme 2. Investigation of acyl-migration within a glucose ring.

We also performed a brief study to understand better the nature of any catalystsubstrate complex suggestive of the possible mode of binding of 6, 7, and 8 to the vancomycin-based substrate. From earlier work,<sup>15</sup> we have compelling evidence that 8

#### **Journal of Medicinal Chemistry**

binds to the ligand binding pocket of vancomycin through a series of hydrogen bonds with the backbone amides (Figure 3b).<sup>55</sup> However, it is unclear if the same sets of amide bonds are also playing a role in recruiting **6** and **7**. To probe this, we performed the acylation reactions with each catalyst in the presence of Boc-Leu-<sup>D</sup>Ala-<sup>D</sup>Ala-OH(1 equiv) as a competing ligand for the binding pocket (see Supporting Information). RP-HPLC analysis confirmed that **8** considerably lost its selectivity (**4a**:**4b**, from 6:1 to 1.6:1) in the presence of the ligand. Moreover, **6** also lost its selectivity to a noticeable extent (**4a**:**4b**, from 1:5 to 1:1.6). On the other hand, **7** had insignificant effect in the presence of the competing ligand. These results further support the hypothesis that 'Xxa-<sup>D</sup>Ala-<sup>D</sup>Pmh' type catalysts interact with the substrate in the canonical ligand binding pocket, and these interactions contribute to high selectivity. As for the catalysts from the legacy library (**6** and **7**), it is difficult to propose a binding model for the observed selectivity, as we have limited knowledge from these experiments.

With the discovery of catalysts **6**, **7**, and **8**, desired mono-acylated products were synthesized in sufficient amounts (100 mg scale reaction) for structural characterization and biological studies. Since starting material **3** is available in multi-gram scale, the lipidation reactions can be done in gram-scale quantity to access these derivatives if necessary (See Supporting Information for details). Following selective acylation, the compounds were purified via RP-MPLC, then the allyl/alloc groups were removed reliably under standard conditions (Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> and PhSiH<sub>3</sub>; Scheme 3). A final RP-HPLC purification yielded the decanoyl-vancomycin analogues **9a** (17 mg, 38% over two steps), **9b** (32 mg, 24% over two steps) and **9c** (11 mg, 24% over two steps) in greater than 95% purity based on RP-HPLC analysis (Please see Supporting Information).

#### **Please Insert Scheme 3**

Scheme 3. Site-selective incorporation of decanoyl motifs into vancomycin scaffold.

The structure of the acyl-vancomycin derivatives 9a, 9b, and 9c were all characterized by 2D-NMR spectroscopy. Figure 7 shows an overlaid edited-HSQC spectrum of native vancomycin (green spots), and **9b** (red and blue spots). All peaks have been assigned using a combination of HSQC, COSY, TOCSY and HMBC experiments and verified with literature reports.<sup>15,56</sup> There are clear changes in the chemical shifts of glucose ring protons relative to that of native vancomycin. The G4 proton has shifted about 1.5 ppm downfield. The  $G_3$  and  $G_5$  protons also showed noticeable downfield shifts. The  $G_1$  and  $G_2$  protons, on the other hand, exhibit a very small downfield shift, while the  $G_6$  protons reflects a very small up-field shift (Figure 7). We also observed a minute perturbation of some of the amino acid  $\alpha$ -protons, perhaps due to subtle conformational changes introduced by the decanoyl moiety. However, almost all of the remaining protons' chemical shifts overlap well with that of native vancomycin. Similarly, 9a and **9c** were also characterized, where the chemical shift of  $G_6$  proton on **9a** and the  $Z_6$  proton on **9c** had significant downfield shift, confirming the site of modification (see Supporting Information).

# **Please Insert Figure 7**

**Figure 7.** An overlay of HSQC-DEPT spectra of vancomycin analogue **9b** (methyls and methines shown in red, and methylenes shown in blue), and native vancomycin (green).

DEPT: distortionless enhancement by polarization transfer.

We then used the newly identified  $G_4$ -selective catalyst to facilitate the synthesis of a library of acyl-vancomycin derivatives to perform a SAR study, wherein the acyl side chain was varied in length and composition at this newly modifiable site. Butanoyl, pentanoyl, hexanoyl, octanoyl, pentenoyl and methyl-adipoyl moieties were selectively incorporated at the  $G_4$  position (**10** – **15**, Figure 8) using catalyst **6**. The different aliphatic chains enable an interrogation of the role of chain length for antibacterial activity. We envisioned that incorporation of a terminal alkene (**14**), or a carboxylate-handle (**15**) could provide a useful chemical handle for further derivatization of vancomycin scaffold as a biomarker or imaging probe.<sup>57</sup> Catalyst **6** was highly faithful in delivering the anticipated selectivity for  $G_4$ -OH site. Each new compound was synthesized using the established protocol with catalyst **6** (20 mol%), and isolated in pure form by RP-HPLC. The site of modification was confirmed by LC-MS/MS analysis and multidimensional NMR spectroscopy (see Supporting Information).

### **Please Insert Figure 8**

Figure 8. Structures of G4-modified vancomycin derivatives.

# **Antibacterial evaluation**

We evaluated the set of nine new lipidated-vancomycin derivatives against a panel of both vancomycin sensitive and vancomycin resistant strains, including methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus faecalis* (VRE). The activity is reported as minimum inhibitory

concentration (MIC) where complete killing effect was observed. Vancomycin, teicoplanin  $A_2$ -2, and linezolid were used as control compounds to compare the MIC values. All of the biologically tested compounds are greater than 95% pure as ascertained by RP-HPLC, as exhibited in the SI (9a, page S-8; 9b, page S-11; 9c, page S-14; 10, page S-16; 11, page S-16; 12, page S-17; 13, page S-17; 14, page S-18; 15, page S-18). All decanoyl-vancomycin derivatives (9a, 9b, and 9c) exhibited remarkable potency against all strains tested, even against a VRE (Van B phenotype) strain. The G<sub>4</sub>-modified analogue 9b is 10 times more active against vancomycinsensitive strains and 64 times more active against a VRE strain (Van B phenotype). In fact, the values are comparable or marginally enhanced in some cases compared to teicoplanin A<sub>2</sub>-2. Remarkably, derivatives 9a, 9b, and 9c exhibit a promising activity of 16 µg/mL against Van A phenotype VRE strain as well. As a comparison, vancomycin and teicoplanin A<sub>2</sub>-2 exhibit an MIC value of 512 µg/mL and 128 µg/mL respectively against Van A phenotype VRE strain based on literature data.<sup>37</sup>

We also evaluated the bioactivity of the derivatives containing shorter acyl chains or functionalized acyl-moieties. The results indicate that analogues containing lipid chain that is smaller than an octanoyl moiety exhibited reduced bioactivity against VRE strains. A clear trend of loss of activity with reduced length of lipid chain is observed. However, the bioactivity is not completely lost compared to native vancomycin. This trend may support the previously proposed cell membrane binding model by which lipidatedvancomycin analogues exhibit potency against VRE strains.<sup>34,35,37</sup> Compounds **14** and **15** retained respectable bioactivity against vancomycin-sensitive strains, suggesting that these sites are potential places for the incorporation of chemical probes for studying

# **Please Insert Table 1**

 Table 1. Antibacterial activity data for lipidated-vancomycin derivatives against

 vancomycin-sensitive and vancomycin-resistant bacteria.

#### CONCLUSION

With the increased emergence of vancomycin resistance among clinically relevant pathogens, significant effort is being directed towards identifying new vancomycin analogues with improved bioactivity. Herein we report our discovery of three unique peptide-catalysts that allow us to incorporate lipid moieties into vancomycin scaffold in a highly site-selective manner. This semi-synthetic approach enables us to modify three different positions (G4, G6, and Z6) on vancomycin. Since enhancing the bioactivity of vancomycin via incorporating lipid motifs is of high interest in literature<sup>37,43,45,46</sup>, our approach provides new opportunities to efficiently modify three distinct positions on vancomycin. We also prepared a series of lipidated vancomycins derivatized at the site for which the newest catalyst capability was achieved, the  $G_4$ -OH group. The antibacterial evaluation revealed that incorporation of a decanoyl group considerably improves vancomycin's activity against MRSA and VRE (Van A and Van B phenotypes). That said, it seems that the added lipophilicity of the presently reported vancomycin derivatives might render them more teicoplanin-like. Since teicoplanin is known to be vulnerable to the development of resistance,<sup>58</sup> it seems much further study

would be required to for the presently reported compounds to contribute to useful therapies.

Ultimately, the site-selective catalysis approach may allow one not only to identify biologically interesting analogues, but perhaps also to study the function of the peripheral hydroxyl groups of vancomycin in a position-specific manner.<sup>57</sup>

#### EXPERIMENTAL PROCEDURES

Materials and instrumentation. All commercially available reagents were purchased and used without further purification, unless otherwise stated. Air and moisture sensitive reactions were done under nitrogen atmosphere employing flame-dried glassware. Commercially available solvents (> 99.0% purity) were used for column chromatography without any further purification. Tetrahydrofuran (THF). dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>), and toluene were purified by a Seca Solvent Purification System from Glass Contour (Nashua, NH). Proton and carbon NMR spectra were recorded on a 600 MHz or 500 MHz spectrometer. Proton chemical shifts are reported in ppm ( $\delta$ ) relative to residual CHCl<sub>3</sub> ( $\delta$  7.26 ppm) or DMSO-d<sub>6</sub> (2.50 ppm). Data are reported as follows: chemical shift (multiplicity [singlet (s), doublet (d), doublet of doublets (dd), doublet of doublets of doublets (ddd), triplet (t), quartet (q), quintet (p), sextet (h), multiplet (m), apparent singlet (app. s), apparent doublet (app. d)], coupling constants [Hz], integration). Carbon chemical shifts are reported in ppm with the respective solvent resonance as the internal standard (CDCl<sub>3</sub>,  $\delta$  77.1 ppm, DMSO-d<sub>6</sub>,  $\delta$ 40.0). Unless otherwise noted, all NMR spectra were acquired at ambient temperature.

Infrared spectra (thin film) were recorded on a FT-IR,  $v_{max}$  (cm<sup>-1</sup>) and are partially reported. Analytical thin-layer chromatography (TLC) was performed using Silica Gel 60 Å F254 precoated plates (0.25 mm thickness). The following visualization methods were used for monitoring reactions and column chromatography: UV absorption by fluorescence quenching; Ninhydrin spray (Ninhydrin: acetic acid: *n*-butanol/ 0.6 g:6 mL:200 mL) or PMA stain (phosphomolybdic acid, H<sub>2</sub>SO<sub>4</sub>). Flash column chromatography was performed using Flash Silica Gel (32-63 micron). Mass spectrometry data were collected using a Ultra high performance LC/MS, which was was performed on a UPLC/MS instrument equipped with a reverse-phase C18 column (1.7 µm particle size, 2.1 x 50 mm), dual atmospheric pressure chemical ionization (API)/electrospray (ESI) mass spectrometry detector, and photodiode array detector. Minimum inhibitory concentrations (MICs) were determined by Micromyx, LLC (Kalamazoo, MI) in accordance with CLSI guidelines.

HR-LC/MS analyses were done on a Waters Acquity UPLC® instrument. **Method 1**: Column = Waters Acquity UPLC® BEH C18 1.7  $\mu$ m, 2.1 Å~ 100 mm; Temperature = 25 °C; Solvent A = H<sub>2</sub>O (0.1% formic acid); Solvent B = MeCN (0.1% formic acid); Flow Rate = 0.8 mL/min; Gradient: Start at 20% B, ramped to 100% B over 3 min, held at 100% B for 1 min. **Method 2**: Column = Waters Acquity UPLC® BEH C8 1.7  $\mu$ m, 2.1 Å~ 100 mm; Temperature = 25 °C; Solvent A = H<sub>2</sub>O (0.1% formic acid); Solvent B = MeCN (0.1% formic acid); Flow Rate = 0.3 mL/min; Gradient: Held at 5% B for 1 min, ramped to 95% B over 5 min and held for 1.5 min.

RP-HPLC analysis and purification were done using these methods. **Method 3**: Column = Waters SymmetryPrep C8 7  $\mu$ m, 300 Å, 7.8 x 300 mm; Temperature = 25 °C;

Solvent A = H<sub>2</sub>O (0.1% formic acid); Solvent B = MeCN (0.1% formic acid); Flow Rate = 4.0 mL/min; Gradient: Held at 5% B for 3 min, ramped to 57% B over 17 min, maintained at 57% B for 5 min, ramped to 99% B over 25 min, held at 99% B for 10 min, ramped to 5% B over 2 min and held for 5 min. **Method 4**: Column = Waters SymmetryPrep C8 7  $\mu$ m, 300 Å, 19 x 300 mm; Temperature = 23 °C; Solvent A = H<sub>2</sub>O (0.1% formic acid); Solvent B = MeCN (0.1% formic acid); Flow Rate = 24 mL/min; Gradient: Held at 5% B for 3 min, ramped to 57% B over 17 min, held at 57% B for 3 min, ramped to 90% B over 20 min, held at 90% B for 3 min, ramped to 5% B over 2 min and held for 2 min. **Method 5**: Column = Waters SymmetryPrep C8 7  $\mu$ m, 300 Å, 19 x 300 mm; Temperature = 23 °C; Solvent A = H<sub>2</sub>O (0.1% formic acid); Solvent B = MeCN (0.1% formic acid); Solvent B = MeCN (0.1% formic acid); B over 20 min, held at 90% B for 3 min, ramped to 5% B over 2 min and held for 2 min. **Method 5**: Column = Waters SymmetryPrep C8 7  $\mu$ m, 300 Å, 19 x 300 mm; Temperature = 23 °C; Solvent A = H<sub>2</sub>O (0.1% formic acid); Solvent B = MeCN (0.1% formic acid); Flow Rate = 24 mL/min; Gradient: Held at 2% B for 7 min, ramped to 60% B over 20 min, ramped to 95% B over 2 min, held at 95% B for 2 min, ramped to 2% B over 2 min and held for 2 min.

RP-MPLC purification was done on a Biotage® instrument. **Method 6**: Column = Biotage SNAP C18, 120 g column with 12-g samplet; Temperature = 23 °C; Solvent A =  $H_2O$ ; Solvent B = MeOH; Flow Rate = 50 mL/min; Gradient: Held at 75% B for 1 column volume (CV), ramped to 80% B over 4 CV, held at 80% B for 6 CV, ramped to 90% B over 1 CV, held at 90% B for 2 CV. **Method 7**: Column = Biotage SNAP C18 60 g column with 12-g samplet; Temperature = 23 °C; Solvent A =  $H_2O$ ; Solvent B = MeCN; Flow Rate = 50 mL/min; Gradient: Held at 5% B for 4 column volume (CV), ramped to 40% B over 4 CV, ramped to 95% B over 18 CV, held at 95% B for 5 CV.

General procedure 1: Screening of peptide catalysts. In a flame-dried small glass vial containing a stir bar, 3 (5 mg, 2.81 µmol, 1 equiv) and peptide catalyst (0.2

#### Journal of Medicinal Chemistry

equiv) were dissolved in THF (100  $\mu$ L) to yield a clear, homogeneous solution. Then, CH<sub>2</sub>Cl<sub>2</sub> (300  $\mu$ L) and PEMP (1.1  $\mu$ L, 6.07  $\mu$ mol, 2 equiv) were added to the vial. Decanoic anhydride (2.1  $\mu$ L, 5.62  $\mu$ mol, 2 equiv) was added subsequently and the reaction mixture was allowed to stir at rt for 24 h. An aliquot (20  $\mu$ L) was taken and quenched with 2-propanol (500  $\mu$ L), and analyzed by HR-LC/MS (Method 2) and RP-HPLC (Method 3). These data were used for preliminary determination of conversion, product selectivity, and site of reaction (See Supporting Information for HPLC data).

General procedure 2: Synthesis of decanoyl-vancomycin derivatives 9a-9c. In a flame-dried 10-mL round bottom flask containing a stir bar, 3 (50 mg, 28.1 µmol, 1 equiv) and the peptide catalyst (5.69 µmol, 0.2 equiv) were dissolved in THF (1 mL) to yield a clear, homogeneous solution. Then,  $CH_2Cl_2$  (2 mL) and PEMP (56.2 µmol, 2 equiv) were added sequentially to the flask, and stirred under N2 atmosphere. A solution of decanoic anhydride (56.2  $\mu$ mol, 2 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added over 10 h using a syringe pump, and the reaction was allowed to stir for an additional 14 h. An aliquot (20  $\mu$ L) was taken and quenched with 2-propanol (500  $\mu$ L), and analyzed by HR-LC/MS (Method 2) and RP-HPLC (Method 3) to determine if the reaction was complete. At this time, the reaction was quenched with 2-propanol (2 mL). The solution was then concentrated in vacuo to a volume of ~1 mL and diluted with another 2 mL of 2propanol. The solution was loaded onto a C18 Biotage samplet and purified using RP-MPLC (Method 7). Fractions containing the desired mono-decanoyl vancomycin derivatives were combined and concentrated to yield the mixture of products as a white residue.

The protected decanoyl vancomycin derivative (15.0 µmol, 1 equiv) was

dissolved in degassed 1,4-dioxane (2 mL) in a 10-mL round bottom flask. The flask was evacuated, and refilled with argon gas four times, and kept under argon atmosphere. To the flask, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (10.6 mg, 15.1 µmol, 1 equiv), and AcOH (0.5 mL) were added quickly, and the flask was sealed with a septum. The flask was again evacuated and refilled with argon gas four times, and kept under argon atmosphere. Then, PhSiH<sub>3</sub> (84 uL, 0.68 mmol, 45 equiv) was added drop wise over 30 min. The reaction was stirred for another 2 h under argon atmosphere at rt. The reaction mixture turned from a cloudy yellow mixture into a darker brown mixture over the course of the reaction. After 2 h of stirring, the reaction mixture was poured into a separatory funnel containing 0.01 M aqueous HCl (100 mL), and washed with hexanes (3 x 100 mL). The aqueous layer was passed through a pad of celite. The filtrate was concentrated to  $\sim 20$  mL, and purified using preparative RP-HPLC (Method 5). The fractions containing the desired product were concentrated *in vacuo* to remove the organic solvent, and the water was removed via freeze-drying to yield **9a-9c** a white residue in greater than 95% purity based on RP-HPLC (Method 3), and 24 - 38% yield over 2 steps.

# Synthesis of G<sub>6</sub>-decanoyl vancomycin derivative 9a using general procedure 2. Protected G<sub>6</sub>-decanoyl vancomycin derivative was isolated as a white residue (29 mg yield; 28.1 µmol scale reaction), which was carried forward for the next reaction. Analytical RP-HPLC retention time of protected G<sub>6</sub>-decanoyl vancomycin derivative (Method 3): 35.5 min; LC-MS (ESI<sup>+</sup>) for C<sub>96</sub>H<sub>117</sub>Cl<sub>2</sub>N<sub>9</sub>O<sub>29</sub>K [M+K]<sup>+</sup>: Calc'd = 1968.697; found = 1968.696.

The deprotected  $G_6$ -decanoyl vancomycin derivative **9a** was isolated as a white residue (17 mg, 38% over two steps). Analytical RP-HPLC retention time of **9a** (Method

# Synthesis of G<sub>4</sub>-decanoyl vancomycin derivative 9b using general procedure 2. Protected G<sub>4</sub>-decanoyl vancomycin derivative was isolated as a white residue (47 mg yield; 56.2 µmol scale reaction), which was carried forward for the next reaction. Analytical RP-HPLC retention time of protected G<sub>4</sub>-decanoyl vancomycin derivative (Method 3): 38.0 min; LC-MS (ESI<sup>+</sup>) for C<sub>96</sub>H<sub>117</sub>Cl<sub>2</sub>N<sub>9</sub>O<sub>29</sub>K [M+K]<sup>+</sup>: Calc'd = 1968.696; found = 1968.695.

The deprotected  $G_4$ -decanoyl vancomycin derivative **9b** was isolated as a white residue (32 mg, 24% over two steps). Analytical RP-HPLC retention time of **9b** (Method 3): 14.2 min; LC-MS (ESI<sup>+</sup>) for  $C_{76}H_{94}Cl_2N_9O_{25}$  [M+H]<sup>+</sup>: Calc'd = 1602.573; found = 1602.582. (See Supporting Information for HPLC & NMR data)

# Synthesis of $Z_6$ -decanoyl vancomycin derivative 9c using general procedure 2. Protected $Z_6$ -decanoyl vancomycin derivative was isolated as a white residue (29 mg yield; 28.1 µmol scale reaction), which was carried forward for the next reaction. Analytical RP-HPLC retention time of protected $Z_6$ -decanoyl vancomycin derivative (Method 3): 39.6 min; LC-MS (ESI<sup>+</sup>) for $C_{96}H_{118}Cl_2N_9O_{29}$ [M+H]<sup>+</sup>: Calc'd = 1930.741; found = 1930.742.

The deprotected Z<sub>6</sub>-decanoyl vancomycin derivative **9c** was isolated as a white residue (11 mg, 24% over two steps). Analytical RP-HPLC retention time of **9c** (Method 3): 12.3 min; LC-MS (ESI<sup>+</sup>) for  $C_{76}H_{94}Cl_2N_9O_{25}$  [M+H]<sup>+</sup>: Calc'd = 1602.573; found = 1602.588. (See Supporting Information for HPLC & NMR data)

General procedure 3: Synthesis of G<sub>4</sub>-acyl vancomycin derivatives 10 – 15. In

a flame-dried 10-mL round bottom flask containing a stir bar, **3** (100 mg, 56.2 mmol, 1 equiv) and catalyst **6** (8 mg, 11.6  $\mu$ mol, 0.2 equiv) were dissolved in THF (2 mL) to yield a clear, homogeneous solution. Then, CH<sub>2</sub>Cl<sub>2</sub> (5 mL) and PEMP (20.3  $\mu$ L, 112.4  $\mu$ mol, 2 equiv) were added sequentially to the flask, and stirred under N<sub>2</sub> atmosphere. A solution of anhydride (112.6  $\mu$ mol, 2 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added over 10 h using a syringe pump, and the reaction was allowed to stir for an additional 14 h. An aliquot (20  $\mu$ L) was taken and quenched with 2-propanol (500  $\mu$ L), and analyzed by HR-LC/MS (Method 2) and RP-HPLC (Method 3) to determine if the reaction was complete. At this time, the reaction was quenched with 2-propanol (2 mL). The solution was then concentrated *in vacuo* to a volume of ~1 mL and diluted with another 2 mL of 2-propanol. The solution was loaded onto a C18 Biotage samplet and purified using RP-MPLC (Method 7). Fractions containing the desired mono-decanoyl vancomycin derivatives were combined and concentrated to yield the mixture of products as a white residue (40 – 50% yield), which was carried forward for the next reaction.

The protected  $G_4$ -acyl vancomycin derivative (28 µmol, 1 equiv) was dissolved in degassed 1,4-dioxane (2 mL) in a 10-mL round bottom flask. The flask was evacuated, and refilled with argon gas four times, and kept under argon atmosphere. To the flask,  $Pd(PPh_3)_2Cl_2$  (19.7 mg, 28 µmol, 1 equiv), and AcOH (0.5 mL) were added sequentially, and the flask was sealed with a septum. The flask was again evacuated and refilled with argon gas four times, and kept under argon atmosphere. Then,  $PhSiH_3$  (157 µL, 1.27 mmol, 45 equiv) was added drop wise over 30 min. The reaction was stirred for another 2 h under argon atmosphere at rt. The reaction mixture turned from a cloudy yellow mixture into a darker brown mixture over the course of the reaction. After 2 h of stirring,

#### Journal of Medicinal Chemistry

the reaction mixture was poured into a separatory funnel containing 0.01 M aqueous HCl (200 mL), and washed with hexanes (3 x 100 mL). The aqueous layer was passed through a pad of celite. The filtrate was concentrated to ~20 mL, and purified using preparative RP-HPLC (Method 5). The fractions containing the desired product were concentrated *in vacuo* to remove the organic solvent, and the water was removed via freeze-drying to yield a white residue (25 – 32% yield over two steps) in greater than 95% purity based on RP-HPLC (Method 3). (See Supporting Information for HPLC & NMR data)

 $G_4$ -butyryl-vancomycin derivative (10): Analogue 10 was synthesized using the general procedure 3 and isolated as a white solid (14.5 mg, 17% over two steps). Analytical RP-HPLC retention time (Method 3): 9.7 min; LC-MS (ESI<sup>+</sup>) for  $C_{71}H_{84}Cl_2N_9O_{25}$  [M+H]<sup>+</sup>: Calc'd = 1518.479; found = 1518.469.

 $G_4$ -pentanoyl-vancomycin derivative (11): Analogue 11 was synthesized using the general procedure 3 and isolated as a white solid (10 mg, 23% over two steps). Analytical RP-HPLC retention time (Method 3): 9.8 min; LC-MS (ESI<sup>+</sup>) for  $C_{71}H_{84}Cl_2N_9O_{25}$  [M+H]<sup>+</sup>: Calc'd = 1532.495; found = 1532.526.

 $G_4$ -hexanoyl-vancomycin derivative (12): Analogue 12 was synthesized using the general procedure 3 and isolated as a white solid (11 mg, 25% over two steps). Analytical RP-HPLC retention time (Method 3): 11.2 min; LC-MS (ESI<sup>+</sup>) for  $C_{72}H_{86}Cl_2N_9O_{25}$  [M+H]<sup>+</sup>: Calc'd = 1546.511; found = 1546.510.

 $G_4$ -octanoyl-vancomycin derivative (13): Analogue 13 was synthesized using the general procedure 3 and isolated as a white solid (14 mg, 32% over two steps). Analytical RP-HPLC retention time (Method 3): 13.2 min; LC-MS (ESI<sup>+</sup>) for  $C_{74}H_{90}Cl_2N_9O_{25}$  [M+H]<sup>+</sup>: Calc'd = 1574.542; found = 1574.540.

 $G_4$ -pentenoyl-vancomycin derivative (14): Analogue 14 was synthesized using the general procedure 3 and isolated as a white solid (18 mg, 21% over two steps). Analytical RP-HPLC retention time (Method 3): 10.2 min; LC-MS (ESI<sup>+</sup>) for  $C_{71}H_{82}Cl_2N_9O_{25}$  [M+H]<sup>+</sup>: Calc'd = 1530.479; found =1530.476.

**G**<sub>4</sub>-methyladipoyl-vancomycin derivative (15): Analogue 15 was synthesized using the general procedure 3 and isolated as a white solid. Analytical RP-HPLC retention time (Method 3): 10.1 min; LC-MS (ESI<sup>+</sup>) for  $C_{73}H_{86}Cl_2N_9O_{27}$  [M+H]<sup>+</sup>: Calc'd = 1590.500; found = 1590.529.

General procedure 4: Competition studies using Boc-Leu-<sup>D</sup>Ala-<sup>D</sup>Ala-OH, a tripeptide ligand for vancomycin. In a flame-dried small glass vial containing a stir bar, 3 (5 mg, 2.81  $\mu$ mol, 1 equiv), Boc-Leu-<sup>D</sup>Ala-<sup>D</sup>Ala-OH (1.1 mg, 2.94  $\mu$ mol, 1 equiv) and peptide catalyst (0.9  $\mu$ mol, 0.3 equiv) were dissolved in THF (100  $\mu$ L) to yield a clear, homogeneous solution. Then, CH<sub>2</sub>Cl<sub>2</sub> (300  $\mu$ L) and PEMP (1.1  $\mu$ L, 6.07  $\mu$ mol, 2 equiv) were added to the vial. Decanoic anhydride (2.1  $\mu$ L, 5.62  $\mu$ mol, 2 equiv) was added subsequently and the reaction mixture was allowed to stir for 24 h at rt. An aliquot (20  $\mu$ L) was taken and quenched with 2-propanol (500  $\mu$ L), and analyzed by HR-LC/MS (Method 2) and RP-HPLC (Method 3). These data were used for preliminary determination of the conversion, product selectivity, and site of reaction (See Supporting Information for HPLC data).

#### ACKNOWLEDGMENT

We are grateful to the National Institute of General Medical Sciences of the United States National Institutes of Health (GM-068649) for support. We also wish to

thank Dr. Brandon S. Fowler for providing peptide catalysts for the initial screening.

# ASSOCIATED CONENT

#### **Supporting Information Availability:**

Figures, schemes and characterization (RP-HPLC data and NMR data) of the compounds

are provided. This material is available free of charge via the Internet at:

http://pubs.acs.org

# AUTHOR INFORMATION

#### **Corresponding Author**

\*Phone: 203-432-9885. Fax: 204-436-4900. E-mail: scott.miller@yale.edu

# **ABBREVIATIONS USED**

NMI – N-methylimidazole; PEMP - 1,2,2,6,6-pentamethylpiperidine; pmh - p(methyl)-

histidine; DEPT: distortionless enhancement by polarization transfer; MSSA -

methicillin-sensitive Staphylococcus aureus; methicillin-resistant Staphylococcus aureus;

VRE – vancomycin-resistant Enterococcus faecalis.

### REFERENCES

(1) Li, J. W. H.; Vederas, J. C. Drug discovery and natural products: End of an era or an endless frontier? *Science* **2009**, *325*, 161-165.

(2) Clardy, J.; Walsh, C. Lessons from natural molecules. *Nature* 2004, *432*, 829-837.

(3) Szychowski, J.; Truchon, J.-F.; Bennani, Y. L. Natural products in medicine: Transformational outcome of synthetic chemistry. *J. Med. Chem.* 2014, 57, 9292-9308.

(4) Fischbach, M. A.; Walsh, C. T. Antibiotics for emerging pathogens.*Science* 2009, *325*, 1089-1093.

(5) Pootoolal, J.; Neu, J.; Wright, G. D. Glycopeptide antibiotic resistance.*Annu. Rev. Pharmacol.* 2002, *42*, 381-408.

(6) Wright, G. D. Antibiotics: A new hope. *Chem. Biol.* **2012**, *19*, 3-10.

(7) James, R. C.; Pierce, J. G.; Okano, A.; Xie, J.; Boger, D. L. Redesign of glycopeptide antibiotics: Back to the future. *ACS Chem. Biol.* **2012**, *7*, 797-804.

(8) Robles, O.; Romo, D. Chemo- and site-selective derivatizations of natural products enabling biological studies. *Nat. Prod. Rep.* **2014**, *31*, 318-334.

(9) Mahatthananchai, J.; Dumas, A. M.; Bode, J. W. Catalytic selective synthesis. *Angew. Chem. Int. Ed.* **2012**, *51*, 10954-10990.

(10) Beale, T. M.; Taylor, M. S. Synthesis of cardiac glycoside analogs by
catalyst-controlled, regioselective glycosylation of digitoxin. *Org. Lett.* 2013, *15*, 1358-1361.

(11) Yoganathan, S.; Yin, N.; He, Y.; Mesleh, M. F.; Gu, Y. G.; Miller, S. J.
An efficient chemical synthesis of carboxylate-isostere analogs of daptomycin. *Org. Biomol. Chem.* 2013, *11*, 4680-4685.

(12) Thaker, M. N.; Wright, G. D. Opportunities for Synthetic Biology in
Antibiotics: Expanding Glycopeptide Chemical Diversity. *ACS Synth. Biol.* 2014,
DOI: 10.1021/sb300092n.

(13) Lewis, C. A.; Miller, S. J. Site-selective derivatization and remodeling of erythromycin A by using simple peptide-based chiral catalysts. *Angew. Chem. Int. Ed.* 2006, *45*, 5616-5619.

(14) Lewis, C. A.; Longcore, K. E.; Miller, S. J.; Wender, P. A. An approach to the site-selective diversification of apoptolidin A with peptide-based catalysts. *J. Nat. Prod.* **2009**, *72*, 1864-1869.

(15) Fowler, B. S.; Laemmerhold, K. M.; Miller, S. J. Catalytic site-selective thiocarbonylations and deoxygenations of vancomycin reveal hydroxyl-dependent conformational effects. *J. Am. Chem. Soc.* **2012**, *134*, 9755-9761.

(16) Pathak, T. P.; Miller, S. J. Site-selective bromination of vancomycin. J.*Am. Chem. Soc.* 2012, *134*, 6120-6123.

(17) Pathak, T. P.; Miller, S. J. Chemical tailoring of teicoplanin with siteselective reactions. *J. Am. Chem. Soc.* **2013**, *135*, 8415-8422.

(18) Han, S.; Miller, S. J. Asymmetric catalysis at a distance: Catalytic, siteselective phosphorylation of teicoplanin. *J. Am. Chem. Soc.* **2013**, *135*, 12414-12421. (19) Ueda, Y.; Mishiro, K.; Yoshida, K.; Furuta, T.; Kawabata, T.
Regioselective diversification of a cardiac glycoside, lanatoside C, by organocatalysis. *J. Org. Chem.* 2012, *77*, 7850-7857.

(20) Yoshida, K.; Furuta, T.; Kawabata, T. Perfectly regioselective acylation of a cardiac glycoside, digitoxin, via catalytic amplification of the intrinsic reactivity. *Tetrahedron Lett.* **2010**, *51*, 4830-4832.

Wilcock, B. C.; Uno, B. E.; Bromann, G. L.; Clark, M. J.; Anderson, T.
M.; Burke, M. D. Electronic tuning of site-selectivity. *Nat. Chem.* 2012, *4*, 996-1003.

(22) Lee, D.; Williamson, C. L.; Chan, L.; Taylor, M. S. Regioselective, borinic acid-catalyzed monoacylation, sulfonylation and alkylation of diols and carbohydrates: Expansion of substrate scope and mechanistic studies. *J. Am. Chem. Soc.* **2012**, *134*, 8260-8267.

(23) Sculimbrene, B. R.; Morgan, A. J.; Miller, S. J. Enantiodivergence in small-molecule catalysis of asymmetric phosphorylation: Concise total syntheses of the enantiomeric D-myo-inositol-1-phosphate and D-myo-inositol-3-phosphate. *J. Am. Chem. Soc.* **2002**, *124*, 11653-11656.

(24) Evans, J. W.; Fierman, M. B.; Miller, S. J.; Ellman, J. A. Catalytic enantioselective synthesis of sulfinate esters through the dynamic resolution of tert-butanesulfinyl chloride. *J. Am. Chem. Soc.* **2004**, *126*, 8134-8135.

(25) Fiori, K. W.; Puchlopek, A. L. A.; Miller, S. J. Enantioselective
sulfonylation reactions mediated by a tetrapeptide catalyst. *Nat. Chem.* 2009, *1*, 630-634.

(26)	Kahne, D.; Leimkuhler, C.; Wei, L.; Walsh, C. Glycopeptide and
lipogl	ycopeptide antibiotics. Chem. Rev. 2005, 105, 425-448.
(27)	Baltz, R. H.; Miao, V.; Wrigley, S. K. Natural products to drugs:
Dapto	omycin and related lipopeptide antibiotics. Nat. Prod. Rep. 2005, 22,
741.	
(28)	Nakama, Y.; Yoshida, O.; Yoda, M.; Araki, K.; Sawada, Y.; Nakar
Xu, S	.; Miura, K.; Maki, H.; Arimoto, H. Discovery of a novel series of
semis	ynthetic vancomycin derivatives effective against vancomycin-resist
bacter	ria. J. Med. Chem. <b>2010</b> , 53, 2528-2533.
(29)	Yarlagadda, V.; Akkapeddi, P.; Manjunath, G. B.; Haldar, J. Meml
active	vancomycin analogues: A strategy to combat bacterial resistance. $J$ .
Chem	. <b>2014</b> , <i>57</i> , 4558-4568.
(30)	Cochrane, S. A.; Lohans, C. T.; Brandelli, J. R.; Mulvey, G.; Arms
G. D.;	; Vederas, J. C. Synthesis and structure-activity relationship studies of
termir	nal analogues of the antimicrobial peptide tridecaptin $A(1)$ . J. Med. C
2014,	57, 1127-1131.
(31)	Lunde, C. S.; Hartouni, S. R.; Janc, J. W.; Mammen, M.; Humphre
Bento	n, B. M. Telavancin disrupts the functional integrity of the bacterial
memb	prane through targeted interaction with the cell wall precursor lipid II
Antim	icrob. Agents Chemother. 2009, 53, 3375-3383.
(32)	Nicolaou, K. C.; Boddy, C. N. C.; Brase, S.; Winssinger, N. Chem
biolog	gy, and medicine of the glycopeptide antibiotics. Angew. Chem. Int. I
1999.	38, 2096-2152.

(33) Butler, M. S.; Hansford, K. A.; Blaskovich, M. A. T.; Halai, R.; Cooper,

M. A. Glycopeptide antibiotics: Back to the future. J. Antibiot. 2014, 67, 631-644.

(34) Nagarajan, R.; Schabel, A. A.; Occolowitz, J. L.; Counter, F. T.; Ott, J. L.
Synthesis and antibacterial activity of N-acyl vancomycins. *J. Antibiot.* 1988, *41*, 1430-1438.

(35) Nagarajan, R.; Schabel, A. A.; Occolowitz, J. L.; Counter, F. T.; Ott, J. L.;
Feltyduckworth, A. M. Synthesis and antibacterial evaluation of N-alkyl
vancomycins. *J. Antibiot.* **1989**, *42*, 63-72.

(36) Williams, D. H.; Bardsley, B. The vancomycin group of antibiotics and the fight against resistant bacteria. *Angew. Chem. Int. Ed.* **1999**, *38*, 1173-1193.

(37) Kerns, R.; Dong, S. D.; Fukuzawa, S.; Carbeck, J.; Kohler, J.; Silver, L.;
Kahne, D. The role of hydrophobic substituents in the biological activity of
glycopeptide antibiotics. *J. Am. Chem. Soc.* 2000, *122*, 12608-12609.

(38) Okano, A.; Nakama, Y.; Schammel, A. W.; Boger, D. L. Total synthesis of [Ψ[C(=NH)NH]Tpg4]vancomycin and its (4-chlorobiphenyl)methyl derivative: Impact of peripheral modifications on vancomycin analogues redesigned for dual d-Ala-d-Ala and d-Ala-d-Lac binding. *J. Am. Chem. Soc.* **2014**, *136*, 13522-13525.

(39) Pinchman, J. R.; Boger, D. L. Probing the role of the vancomycin E-ring aryl chloride: Selective divergent synthesis and evaluation of alternatively substituted E-ring analogues. *J. Med. Chem.* **2013**, *56*, 4116-4124.

(40) Ashford, P.-A.; Bew, S. P. Recent advances in the synthesis of new glycopeptide antibiotics. *Chem. Soc. Rev.* **2012**, *41*, 957-978.

(41) Liu, Y. C.; Li, Y. S.; Lyu, S. Y.; Hsu, L. J.; Chen, Y. H.; Huang, Y. T.;
Chan, H. C.; Huang, C. J.; Chen, G. H.; Chou, C. C.; Tsai, M. D.; Li, T. L.
Interception of teicoplanin oxidation intermediates yields new antimicrobial scaffolds. *Nat. Chem. Biol.* 2011, *7*, 304-309.

(42) Lyu, S. Y.; Liu, Y. C.; Chang, C. Y.; Huang, C. J.; Chiu, Y. H.; Huang, C. M.; Hsu, N. S.; Lin, K. H.; Wu, C. J.; Tsai, M. D.; Li, T. L. Multiple complexes of long aliphatic N-acyltransferases lead to synthesis of 2,6-diacylated/2-acyl-substituted glycopeptide antibiotics, effectively killing vancomycin-resistant Enterococcus. *J. Am. Chem. Soc.* 2014, *136*, 10989-10995.

(43) Sharman, G. J.; Try, A. C.; Dancer, R. J.; Cho, Y. R.; Staroske, T.;
Bardsley, B.; Maguire, A. J.; Cooper, M. A.; O'Brien, D. P.; Williams, D. H. The roles of dimerization and membrane anchoring in activity of glycopeptide antibiotics against vancomycin-resistant bacteria. *J. Am. Chem. Soc.* 1997, *119*, 12041-12047.

(44) Higgins, D. L.; Chang, R.; Debabov, D. V.; Leung, J.; Wu, T.; Krause, K.
A.; Sandvik, E.; Hubbard, J. M.; Kaniga, K.; Schmidt, D. E.; Gao, Q. F.; Cass, R.
T.; Karr, D. E.; Benton, B. M.; Humphrey, P. P. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant *Staphylococcus aureus*. *Antimicrob*. *Agents Chemother*. **2005**, *49*, 1127-1134.

(45) Ge, M.; Chen, Z.; Onishi, H. R.; Kohler, J.; Silver, L. L.; Kerns, R.;Fukuzawa, S.; Thompson, C.; Kahne, D. Vancomycin derivatives that inhibit

peptidoglycan biosynthesis without binding D-Ala-D-Ala. *Science* **1999**, 284, 507-511.

(46) Chen, L.; Walker, D.; Sun, B.; Hu, Y.; Walker, S.; Kahne, D. Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 5658-5663.

(47) Roy, R. S.; Yang, P.; Kodali, S.; Xiong, Y. S.; Kim, R. M.; Griffin, P. R.;Onishi, H. R.; Kohler, J.; Silver, L. L.; Chapman, K. Direct interaction of a vancomycin derivative with bacterial enzymes involved in cell wall biosynthesis.

*Chem. Biol.* **2001**, *8*, 1095-1106.

(48) Thompson, C.; Ge, M.; Kahne, D. Synthesis of vancomycin from the aglycon. J. Am. Chem. Soc. **1999**, *121*, 1237-1244.

(49) Griffith, B. R.; Krepel, C.; Fu, X.; Blanchard, S.; Ahmed, A.; Edmiston,
C. E.; Thorson, J. S. Model for antibiotic optimization via neoglycosylation:
Synthesis of liponeoglycopeptides active against VRE. *J. Am. Chem. Soc.* 2007, *129*, 8150-8155.

(50) Davie, E. A. C.; Mennen, S. M.; Xu, Y. J.; Miller, S. J. Asymmetric catalysis mediated by synthetic peptides. *Chem. Rev.* **2007**, *107*, 5759-5812.

(51) Miller, S. J. In search of peptide-based catalysts for asymmetric organic synthesis. *Acc. Chem. Res.* **2004**, *37*, 601-610.

(52) Nitanai, Y.; Kikuchi, T.; Kakoi, K.; Hanmaki, S.; Fujisawa, I.; Aoki, K. Crystal structures of the complexes between vancomycin and cell-wall precursor analogs. *J. Mol. Biol.* **2009**, *385*, 1422-1432.

(53) Conversion and selectivity data based on uncorrected RP-HPLC analysis at 220 nm.

(54) Fowler, B. S.; Mikochik, P. J.; Miller, S. J. Peptide-catalyzed kinetic
resolution of formamides and thioformamides as an entry to nonracemic amines. *J. Am. Chem. Soc.* 2010, *132*, 2870-2871.

(55) Han, S.; Le, B. V.; Hajare, H. S.; Baxter, R. H. G.; Miller, S. J. X-ray crystal structure of teicoplanin A2-2 bound to a catalytic peptide sequence via the carrier protein strategy. *J. Org. Chem.* **2014**, *79*, 8550-8556.

(56) Pearce, C. M.; Williams, D. H. Complete assignment of the C-13 nmrspectrum of vancomycin. *J. Chem. Soc. Perkin Trans.* 2 **1995**, 153-157.

(57) Tiyanont, K.; Doan, T.; Lazarus, M. B.; Fang, X.; Rudner, D. Z.; Walker,
S. Imaging peptidoglycan biosynthesis in *Bacillus subtilis* with fluorescent antibiotics. *Proc. Natl. Acad. Sci. USA* 2006, *103*, 11033-11038.

(58) Holmes, N. E.; Ballard, S. A.; Lam, M. M. C.; Johnson, P. D. R.; Grayson,
M. L.; Stinear, T. P.; Howden, B. P. Genomic analysis of teicoplanin resistance
emerging during treatment of vanB vancomycin-resistant *Enterococcus faecium*infections in solid organ transplant recipients including donor-derived cases. *J. Antimicrob. Chemother.* 2013, 68, 2134-2139.



**Figure 1.** (a) A schematic outline of various group transfer reactions catalyzed by Pmhbased peptides for polyol modifications. (b) A representative set of catalyst-dependent maneuvers leading to two unique deoxygenation vancomycin analogues.<sup>15</sup>





 $A_2-2(2)$ 



**Figure 3** (a) a co-crystal structure of the ligand, N-Ac-Lys(Ac)-<sup>D</sup>Ala-<sup>D</sup>Ala (yellow) bound to vancomycin and (b) a drawing of a segment of a designed catalyst over the ligand (PDB 1FVM).<sup>52</sup>





Scheme 1 Exploration of catalysts for site-selective modification of 3.



**Figure 4** RP-HPLC traces for uncatalyzed, NMI (0.2 equiv) catalyzed, and peptide **5** catalyzed reactions of **3** using decanoyl anhydride.



Figure 5 Structures of catalysts identified for selective lipidation.







Figure 6 RP-HPLC traces for catalyst dependent reactivity of **3** with decanoyl anhydride. (a)  $G_4$ -selective catalysis with **6**, (b)  $Z_6$ -selective catalysis with **7**, and (c)  $G_6$ -selective catalysis with **8**.



Scheme 2 Investigation of acyl-migration within a glucose ring.



Scheme 3 Site-selective incorporation of decanoyl motifs into vancomycin scaffold.



**Figure 7** An overlay of HSQC-DEPT spectra of vancomycin analogue **9b** (methyls and methines shown in red, and methylenes shown in blue), and native vancomycin (green). DEPT: distortionless enhancement by polarization transfer.



**Figure 8** Structures of G<sub>4</sub>-modified vancomycin derivatives.

 Table 1
 Antibacterial activity data for lipidated-vancomycin derivatives against

 vancomycin-sensitive and vancomycin-resistant bacteria.

Compound	S. aureus	S. aureus	E. faecalis	E. faecalis	E. faecalis
	(MSSA)	(MRSA)	(Van S)	(Van B)	(Van A)
	ATCC	ATCC	ATCC	ATCC	MMX
	29213	43300	29212	51299	486 <sup>a</sup>
9a	0.25	0.25	0.5	1	16
9b	0.12	0.12	0.25	0.25	16
9с	0.25	0.5	0.25	0.5	16
10	4	4	8	32	>64
11	2	4	4	32	>32
12	2	2	4	16	>64
13	0.5	0.5	1	8	>64
14	4	4	8	32	>32
15	4	4	8	64	>64
Vancomycin	. 1	1	2	16	>64 <sup>b</sup>
Teicoplanin	1	0.5	0.25	0.25	>64 <sup>b</sup>
Linezolid	4	4	2	2	2

<sup>a</sup>MMX: Micromyx isolate number. <sup>b</sup>Vancomycin exhibits an MIC of 512  $\mu$ g/mL and teicoplanin A<sub>2</sub>-2 exhibits an MIC of 128  $\mu$ g/mL against Van A phenotype VRE strain, based on a literature report.<sup>37</sup>





# **Table of Contents Graphic**

